HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: FDA on glycerin

This article was originally published in The Rose Sheet

Executive Summary

FDA on glycerin: The agency does not plan to include glycerin at concentrations less than 20% in the final monograph for OTC skin protectants, FDA tells Warner-Lambert in an Aug. 23 response to a study submitted by the firm. The study compares groups of subjects who used hand lotions containing .2 allantoin and either 2%, 10% or 18% glycerin with a no-treatment control group. FDA determined that the study "fails to demonstrate that 2%, 10% or 18% glycerin is effective for the indication `helps prevent and temporarily protects chafed, chapped, cracked, or windburned skin and lips'" -- the indication for hand lotions with 20-45% glycerin in the tentative final monograph...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel